A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML

Trial Profile

A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Decitabine (Primary) ; Panobinostat (Primary)
  • Indications Acute myeloid leukaemia; Refractory anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen-Cilag; Novartis
  • Most Recent Events

    • 06 Dec 2016 Interim results (n=54) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
    • 18 Dec 2013 New source identified and integrated Netherlands Clinical Trials Register
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top